Document is current
Any future updates will be listed below
-
Authors
L’Hostis, Adèle
Palgen, Jean-Louis
Perrillat-Mercerot, Angélique
Peyronnet, Emmanuel
Jacob, Evgueni
Bosley, James
Duruisseaux, Michaël
Toueg, Raphaël
Lefèvre, Lucile
Kahoul, Riad https://orcid.org/0000-0002-6181-7466
Ceres, Nicoletta
Monteiro, Claudio https://orcid.org/0000-0001-6982-310X
-
Funding
Funding for this research was provided by:
Novadiscovery SA
Janssen cilag France
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 21 June 2023
First Online: 31 July 2023
Competing interests
: The authors declare the following financial competing interests: A.L.H., J.L.P., A.P.M., E.P., E.J., J.B., R.K., N.C., and C.M. are employed by Novadiscovery SA. R.T. and L.L. are employed by Janssen-Cilag. M.D. reports receipt of honoraria for academic/accredited talks from AstraZeneca, Guardant Health, MSD Oncology, BMS, Takeda. M.D. reports membership of an advisory board and consultancy for AstraZeneca, MSD Oncology, BMS, Pfizer, Roche, Takeda, Boehringer Ingelheim, Janssen Oncology, Amgen, AbbVie, Elevation Oncology, Eli Lilly. M.D. reports receipt of research grants (funds to institution) from Eli Lilly and Nanostring.
